The group's principal activities are to develop and manufacture iron replacement therapeutics and magnetic resonance imaging (mri) contrast agents. The products of the group are used in the treatment of chronic anemia and diagnostic imaging agents. Mri is the diagnostic imaging technique of choice for the central nervous system and is widely used for the imaging of ligaments and tendons. The therapeutic agents are used in conjunction with magnetic resonance imaging (mri) in the diagnosis of cancer and other diseases. The contrast agents developed by the group improve the quality of diagnostic images by increasing the contrast between different internal structures. The principal brand names of the group include feridex i.v. And combidex. The products of the group are marketed in the United States, Europe, Argentina, Japan, South Korea, China and Israel.
